Author(s)

Sanjay Hinduja¹, Adnan Khan², Uzair B. Chaudhary^3*

¹Department of Internal Medicine, University of California San Francisco-Fresno, Fresno, CA, USA.
²Wayne State University School of Medicine, Detroit, MI, USA.
³Division of Hematology/Oncology, University of California San Francisco-Fresno, Fresno, CA, USA.

Androgen deprivation therapy has been the mainstay of treatment for management of metastatic hormone sensitive prostate cancer. Recently conducted randomized controlled trials with docetaxel based chemotherapy have shed light on benefit of early use chemotherapy for hormone sensitive prostate cancer. In this review, we aim to comprehensively describe recent trials which are changing the paradigm in support of up front use of docetaxel based chemotherapy for metastatic hormone sensitive prostate cancer.

Metastatic Prostate Cancer, Hormone Sensitive Disease

Hinduja, S. , Khan, A. and Chaudhary, U. (2017) Role of Chemohormonal Therapy in Management of Patients with Metastatic Hormone Sensitive Prostate Cancer. Journal of Cancer Therapy, 8, 1149-1159. doi: 10.4236/jct.2017.813098.